ProfileGDS5678 / 1443241_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 33% 34% 34% 33% 32% 33% 42% 51% 32% 34% 33% 32% 37% 34% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.7802233
GSM967853U87-EV human glioblastoma xenograft - Control 22.7620734
GSM967854U87-EV human glioblastoma xenograft - Control 32.7651734
GSM967855U87-EV human glioblastoma xenograft - Control 42.7065133
GSM967856U87-EV human glioblastoma xenograft - Control 52.6780632
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.8398633
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.0397542
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.2175651
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.6983332
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.7490634
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.7481533
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.7033932
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.840137
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.7560534